Biogen (BIIB) PT Raised to $360 at Oppenheimer
Get Alerts BIIB Hot Sheet
Price: $208.87 +2.44%
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 6 | New: 3
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 6 | New: 3
Join SI Premium – FREE
Oppenheimer analyst Jay Olson raised the price target on Biogen (NASDAQ: BIIB) to $360.00 (from $350.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Citi Upgrades Suzuki Motor Corp (7269:JP) (SZKMY) to Buy
- Toei co Ltd (9605:JP) PT Raised to JPY6,100 at Nomura/Instinet
- Vera Therapeutics (VERA) PT Lowered to $80 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share